about
Interaction of occupational and personal risk factors in workforce health and safetyRole of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Drug-induced liver injury: present and futureHepatotoxicity observed in clinical trials of aplaviroc (GW873140)Immunotoxicogenomics: gene expression and immunotoxicology in the age of genomicsIs There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?Cellular imaging: a key phenotypic screening strategy for predictive toxicologyMicroRNAs in Drug-induced Liver InjuryStem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver InjuryAcetaminophen-induced Liver Injury: from Animal Models to HumansThe Nuremberg Code subverts human health and safety by requiring animal modelingMechanisms of drug-induced liver injuryThe role of transporters in toxicity and diseaseStem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuriesTranslational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug DiscoveryKey Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansAdvances in Engineered Liver Models for Investigating Drug-Induced Liver InjuryThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityTranslating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significanceHigh-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markersBaicalin Attenuates IL-17-Mediated Acetaminophen-Induced Liver Injury in a Mouse ModelStem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injuryc-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in miceDrug-induced liver injury: recent advances in diagnosis and risk assessment.Organs-on-chips: breaking the in vitro impasse.Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies.High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Normal atmospheric oxygen tension and the use of antioxidants improve hepatocyte spheroid viability and function.ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspectiveDiscernment of possible mechanisms of hepatotoxicity via biological processes over-represented by co-expressed genesDiagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat.HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease.Redox regulation of tumor necrosis factor signalingThe role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice.Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1.
P2860
Q23919248-A0B1EC6C-8EB3-4109-B46E-1D327BEB6568Q24564203-1CFAF4CC-A384-414C-B2EA-D07AE58C598AQ24630227-FDA6EA65-0444-43C2-9293-2EDAABB5B923Q24641929-D1C3067E-3690-40D2-AE8D-76A02D418A17Q24855057-871F6BDE-AD64-460B-9AE5-31CEC8EF957DQ26749381-A3D4EA36-DFD3-4F60-B0D3-B165BB7D3752Q26772999-D43AE6BC-1E9A-4342-A411-3B79DECAE774Q26781577-9C60F7C1-A281-440B-8AC5-4CF6DC0C6863Q26781801-F119602B-5A2C-4DB6-95B0-6176BDB2B44EQ26781923-B009A9DA-5DD5-4601-846C-BA4A3BEB18BEQ26781944-807ABC1F-2FB9-4C84-9B70-BF47A62DF412Q26866469-1ABA6330-8B2B-4148-A206-09F076C10774Q26998806-81431732-4F72-4917-AA52-600807072EDDQ26999452-B2DE68CC-B265-4CF7-A3FA-CCE38511B5DDQ27024267-387D74FF-6FCA-4616-B1D6-D1DFC0B9957DQ27902347-432354C1-CEDF-457E-ADDB-D2FD9E044ADDQ28072402-3E1B0400-A8A0-4E68-9CF1-516A3383167EQ28075991-97D43FDE-8808-4D48-B743-EA73065FCC1DQ28077505-1D80E7AF-A09C-4CB0-B1F6-45A8C1408483Q28080256-88D12328-CF53-44F9-B780-BE1389C32497Q28478443-A3A3BC1A-A830-4290-A3DD-B75D157B58D3Q28538041-9E68BABD-1217-40DF-9CA4-A4DCB60B4C7BQ28539567-9AA5C78F-E679-4574-99BE-398DD85D6036Q28553587-F20AA252-6455-48DF-9AB4-905F62168D48Q28818235-E8C1EDBC-4AE1-4B98-8F3C-8CDAE41F6251Q30010257-FC4DA102-3229-4E3C-BEA2-65686AD67AA4Q30235089-F28E7C1C-4C36-4AFD-ACE4-F58FCB10705DQ30413796-7AA718B2-68B8-46EE-83B1-C02031B3D938Q30852962-B68DA7AB-9F82-441E-8971-8ADF1B959C88Q30927447-5A94E54D-A258-4630-955B-1EB51DD9686CQ33239100-0064F0F3-F750-45F8-8614-0064A3C236AAQ33410375-B67C35FA-0CF4-4351-8E26-C15D770D33E8Q33449374-A1AF3BE0-2DA1-4A9D-8A53-1689C746E4BDQ33469822-D40A18FC-0534-4ADA-AC56-87582859FB79Q33470726-3F196A58-0819-4A27-A0CB-1D29D3F900CFQ33577715-806F82B6-75CB-4333-B80E-571E7E697518Q33642614-8EFC44AA-285B-4C03-9B5D-372F19E28912Q33644327-C3C18B83-6C6D-46AF-A777-A599BE22CD3BQ33653566-0565EE2D-EECC-411B-8939-7FDCF9416FFDQ33707120-267524B0-EFDB-4940-9660-5B6518CE1E23
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Idiosyncratic drug hepatotoxicity.
@ast
Idiosyncratic drug hepatotoxicity.
@en
type
label
Idiosyncratic drug hepatotoxicity.
@ast
Idiosyncratic drug hepatotoxicity.
@en
prefLabel
Idiosyncratic drug hepatotoxicity.
@ast
Idiosyncratic drug hepatotoxicity.
@en
P2860
P356
P1476
Idiosyncratic drug hepatotoxicity.
@en
P2093
Neil Kaplowitz
P2860
P2888
P304
P356
10.1038/NRD1750
P577
2005-06-01T00:00:00Z